Sephabel SA
4.3 FTEThe score of Sephabel shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity -1 % Total assets -6 % Headcount (avg FTE) -10 %
Accounts of the company itself (not consolidated).
The full file covers 16 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sephabel's annual accounts
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | −10,698 € | ||||
| Equity | 706,579 € | ||||
| Cash | 135,114 € | ||||
| EBITDA | 77,911 € | ||||
| Total assets | €1.21m |
Filed annual accounts
- Year ended 31 Dec 2024filed on 24 Jul 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 09 Jun 2023
- Year ended 31 Dec 2021filed on 13 Jun 2022
- Year ended 31 Dec 2020filed on 07 Jun 2021
Sephabel's financial analysis
- Solvency58.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sephabel
Sephabel's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0449.100.694
- VAT number
- BE0449100694
- Peppol
- Registered · 0208:0449100694 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 29 Dec 1992
- Registered office
- 3001 Leuven
- Size
- Micro · 4.3 FTE
- Latest accounts
- 2024 · filed on 24 Jul 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Sephabel (SA) has been based in Leuven since 1992, active in: retail sale of pharmaceutical products. For 2024, it reports a net loss of 10,698 € and equity of 706,579 €; its revenue is not published. With 4.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 58.2%, above the median of its sector (44.2%).
Companies similar to Sephabel
Companies in the same business, of comparable size and area, outside its group.
- Dekerk Retail sale of pharmaceutical products Tienen · balance sheet €1.12m
- Apotheek Hauspie A. Retail sale of pharmaceutical products Diksmuide · balance sheet €1.20m
- Pharmacie City Retail sale of pharmaceutical products Schaerbeek · balance sheet €1.19m
- Ma Ressource Santé Retail sale of pharmaceutical products Woluwe-Saint-Lambert · balance sheet €1.17m
- Bessemer Apotheek Retail sale of pharmaceutical products Lanaken · balance sheet €1.27m
- Trimephar Retail sale of pharmaceutical products Faimes · balance sheet €1.30m
- Apotheker Steven Vrijdag Retail sale of pharmaceutical products Dendermonde · balance sheet €1.32m
- Parapharmacie Discount Andenne Retail sale of pharmaceutical products Andenne · balance sheet €1.34m
Frequently asked questions about Sephabel
What is the revenue of Sephabel?
Sephabel files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Sephabel?
In Belgium, the VAT number is the company number prefixed with BE: BE0449100694 for Sephabel, if the company is VAT-registered. Its company number (CBE) is 0449.100.694.
Where is the registered office of Sephabel?
According to the CBE register, the registered office of Sephabel is in 3001 Leuven.
What is the equity of Sephabel?
At the close of the 2024 financial year, the equity of Sephabel amounts to 706,579 €, a solvency of 58.2% of total assets.
How many people work at Sephabel?
4.3 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Sephabel?
The register lists 3 active mandates at Sephabel. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sephabel
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →